These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37090727)

  • 41. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
    Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast cancer resistance mechanisms: challenges to immunotherapy.
    Hanna A; Balko JM
    Breast Cancer Res Treat; 2021 Nov; 190(1):5-17. PubMed ID: 34322780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions.
    Schenk EL
    Transl Lung Cancer Res; 2023 Feb; 12(2):322-336. PubMed ID: 36895933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Attili I; Tarantino P; Passaro A; Stati V; Curigliano G; de Marinis F
    Lung Cancer; 2021 Apr; 154():151-160. PubMed ID: 33684660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting Immunometabolism Mediated by CD73 Pathway in
    Passarelli A; Aieta M; Sgambato A; Gridelli C
    Front Immunol; 2020; 11():1479. PubMed ID: 32760402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
    Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
    Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory (FoxP3
    Koh J; Hur JY; Lee KY; Kim MS; Heo JY; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Sci Rep; 2020 Nov; 10(1):18994. PubMed ID: 33149213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CAR-T Immunotherapy and Non-small Cell Lung Cancer: Bottleneck and Dawn].
    Zhang L; Li H; Zhang F; Wang S; Li G
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):916-920. PubMed ID: 32810975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer.
    Russell É; Conroy MJ; Barr MP
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New Immuno-oncology Targets and Resistance Mechanisms.
    Tokaz MC; Baik CS; Houghton AM; Tseng D
    Curr Treat Options Oncol; 2022 Sep; 23(9):1201-1218. PubMed ID: 35980521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
    Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
    Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.
    Tancoš V; Blichárová A; Plank L
    Klin Onkol; 2022; 35(5):372-376. PubMed ID: 36443097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
    Tian Y; Zhai X; Yan W; Zhu H; Yu J
    Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
    La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
    Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective.
    Xiao Y; Zhang L; Zhu J; Zhang Y; Yang R; Yan J; Huang R; Zheng C; Xiao W; Huang C; Wang Y
    Biomed Pharmacother; 2021 Nov; 143():112105. PubMed ID: 34560533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)-a randomized controlled trial.
    Holmen Olofsson G; Mikkelsen MK; Ragle AM; Christiansen AB; Olsen AP; Heide-Ottosen L; Horsted CB; Pedersen CMS; Engell-Noerregaard L; Lorentzen T; Persson GF; Vinther A; Nielsen DL; Thor Straten P
    BMC Cancer; 2022 Mar; 22(1):246. PubMed ID: 35247994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.